Viking Therapeutics Inc (MIL:1VKTX)
€ 27.4 -0.20 (-0.72%) Market Cap: 3.17 Bil Enterprise Value: 2.74 Bil PE Ratio: 0 PB Ratio: 9.07 GF Score: 12/100

Viking Therapeutics, Inc. at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2026 / 07:20PM GMT
Release Date Price: €27.4 (-0.72%)
Michael Ulz
Morgan Stanley & Co Ltd - Analyst

All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here. It's my pleasure to introduce the team from Viking Therapeutics. To my immediate left is Brian Lian, CEO. To his left is Neil Aubuchon, Chief Commercial Officer; and to his left is Greg Zante, CFO.

But before we get started, I just need to read a quick disclaimer for important disclosures. Please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. (Event Instructions) And maybe with that, Brian, I can just hand it over to you to make some introductory comments, and then we can go into Q&A.

Brian Lian
Viking Therapeutics, Inc. - President and Chief Executive Officer, Director

Sure. Sure. No. Thanks a lot to Morgan Stanley for the invitation. We've got a great schedule and really happy to be here.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot